Zongchao Mo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zongchao Mo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Changhong Liang
Department of Radiology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
1 shared publication Fangping Xu
Department of Pathology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China
1 shared publication- Haixia Shang
Division of Life Science, Department of Chemical and Biological Engineering, and State Key Laboratory of Nervous System Disorders, The Hong Kong University of Science and Technology, Hong Kong, SAR, China
1 shared publication Haoyu Wang
Division of Life Science, Department of Chemical and Biological Engineering, and State Key Laboratory of Nervous System Disorders, The Hong Kong University of Science and Technology, Hong Kong, SAR, China
1 shared publication- Huan Lin
Department of Radiology, Guangdong Provincial Peoples Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
1 shared publication - Jiguang Wang
The Hong Kong University of Science and Technology
1 shared publication
Latest Publications
- Open Access
- 4 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (27) , eadu1521
Multiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer
Neoadjuvant therapy has been widely used in breast cancer, but treatment response varies among individuals. We conducted multiomic profiling on tumor samples from 149 Chinese patients with breast cancer across ER − HER2 + , ER + HER2 + , and ER − HER2 − subtypes, categorizing outcomes as pathologic complete response (pCR; n = 81) or residual disease (RD; n = 68). We identified distinct molecular features linked to pCR in each subtype: elevated cell proliferation in patients with ER − HER2 − pCR, higher CDKN2A methylation in patients with ER − HER2 − RD, increased KIT methylation in patients with ER − HER2 + RD, and MAP4K1 hypermethylation in patients with ER + HER2 + RD. These findings were subsequently validated in independent datasets. By integrating clinical and multiomic data, we developed MOPCR, a subtype-specific machine learning model that outperformed single-omic approaches in predicting treatment response. MOPCR demonstrated potential generalizability across cohorts and provided preliminary stratification of patient subgroups with higher pCR probability, offering valuable insights for precision cancer management.
- 4 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (27) , eadu1521
Open AccessMultiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer
Neoadjuvant therapy has been widely used in breast cancer, but treatment response varies among individuals. We conducted multiomic profiling on tumor samples from 149 Chinese patients with breast cancer across ER − HER2 + , ER + HER2 + , and ER − HER2 − subtypes, categorizing outcomes as pathologic complete response (pCR; n = 81) or residual disease (RD; n = 68). We identified distinct molecular features linked to pCR in each subtype: elevated cell proliferation in patients with ER − HER2 − pCR, higher CDKN2A methylation in patients with ER − HER2 − RD, increased KIT methylation in patients with ER − HER2 + RD, and MAP4K1 hypermethylation in patients with ER + HER2 + RD. These findings were subsequently validated in independent datasets. By integrating clinical and multiomic data, we developed MOPCR, a subtype-specific machine learning model that outperformed single-omic approaches in predicting treatment response. MOPCR demonstrated potential generalizability across cohorts and provided preliminary stratification of patient subgroups with higher pCR probability, offering valuable insights for precision cancer management.